Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome

Current Opinion in Rheumatology

Volumn 24, Issue 5, 2012, Pages 451-456

  Coca, Andreea ^a   Sanz, Iñaki ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAMINERCEPT; BELIMUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; LYMPHOTOXIN BETA RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; B LYMPHOCYTE; B LYMPHOCYTE DEPLETION; CELL SURVIVAL; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LYMPHOCYTE DEPLETION; SJOGREN'S SYNDROME;

EID: 84864885318     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835707e4     Document Type: Review

References (27)

1. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:1215-1226.
2. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63:3918-3930.
3. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721-731.
4. Lightstone L. Lupus nephritis: where are we now? Curr Opin Rheumatol 2010; 22:252-256.
5. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011; 20:709-716.
6. Sanz I. Connective tissue diseases: targeting B cells in SLE-good news at last! Nat Rev Rheumatol 2011; 7:255-256.
7. Bosma A, Abdel-Gadir A, Isenberg David A, et al. Lipid-antigen presentation by CD1d + B Cells is essential for the maintenance of invariant natural killer T cells. Immunity 2012; 36:477-490.
8. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56:3044-3056.
9. Blair PA, Noreñ a LY, Flores-Borja F, et al. CD19 +CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32:129-140.
10. Horowitz DL, Furie R. Belimumab is approved by the FDA: what more do we need to know to optimize decision making? Curr Rheumatol Rep 2012; 26:318-323.
11. Scholz JL, Crowley JE, Tomayko MM, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci USA 2008; 105:15517-15522.
12. Merrill JT, Ginzler EM, Wallace DJ, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 5:34564.
13. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheumatism 2012; 64:2328-2337.
14. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, doubleblind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010; 62:201-210.
15. Hansen A, Lipsky PE, Dorner T. B cells in Sjogren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. Arthritis Res Ther 2007; 9:218.
16. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52:2740-2750.
17. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:960-968.
18. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57:310-317.
19. Meiners PM, Vissink A, Kallenberg CG, et al. Treatment of primary Sjogren's syndrome with anti-CD20 therapy (rituximab): a feasible approach or just a starting point? Expert Opin Biol Ther 2011; 11:1381-1394.
20. Abdulahad WH, Meijer JM, Kroese FG, et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjogren's syndrome: a double-blind, placebo-controlled study. Arthritis Rheum 2011; 63:1116-1123.
21. Devauchelle-Pensec V, Morvan J, Rat AC, et al. Effects of rituximab therapy on quality of life in patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2011; 29:6-12.
22. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab. Ann Rheum Dis 2012.
23. Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2012; 71:84-87.
24. Mekinian A, Ravaud P, Larroche C, et al. Rituximab in central nervous system manifestations of patients with primary Sjogren's syndrome: results from the AIR registry. Clin Exp Rheumatol 2012; 30:208-212.
25. Hamza N, Bootsma H, Yuvaraj S, et al. Persistence of immunoglobulinproducing cells in parotid salivary glands of patients with primary Sjogren's syndrome after B cell depletion therapy. Ann Rheum Dis 2012.
26. Fava RA, Browning JL, Gatumu M, et al. LTBR-pathway in Sjogren's syndrome: CXCL13 levels and B-cell-enriched ectopic lymphoid aggregates in NOD mouse lacrimal glands are dependent on LTBR. Advances in TNF Family Research. In: Edited by: Wallach D, Kovalenko A, Feldmann M. Springer New York; 2011;691:383-390.
27. Fava RA, Kennedy SM, Wood SG, et al. Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjogren's syndrome. Arthritis Res Ther 2011; 13:R182.